PT Kalbe Farma Tbk (FRA:LCLA) Accumulated Depreciation: € Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LCLA PT Kalbe Farma Tbk FRA:LCLA
81 GF Score
Price €0.04
GF Value €0.07
! 3 Warning Signs
View Full Analysis

What is PT Kalbe Farma Tbk Accumulated Depreciation?

PT Kalbe Farma Tbk FRA:LCLA 81 Accumulated Depreciation is € Mil as of Jun. 2026. GuruFocus rates FRA:LCLA with a GF Score™ of 81/100 and a GF Value™ of €0.07. The stock has 3 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

PT Kalbe Farma Tbk's annual accumulated depreciation increased from Dec. 2023 (€-332 Mil) to Dec. 2024 (€-376 Mil) but then stayed the same from Dec. 2024 (€-376 Mil) to Dec. 2025 (€-350 Mil).

PT Kalbe Farma Tbk Accumulated Depreciation Related Terms

PT Kalbe Farma Tbk Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for PT Kalbe Farma Tbk's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Kalbe Farma Tbk Accumulated Depreciation Chart

PT Kalbe Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -270.13 -307.09 -332.39 -376.01 -350.08

PT Kalbe Farma Tbk Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
FRA:LCLA
81GF Score
PT Kalbe Farma Tbk FRA:LCLA
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Kalbe Farma Tbk Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of € Mil mean?
PT Kalbe Farma Tbk (FRA:LCLA) has a Accumulated Depreciation of € Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on PT Kalbe Farma Tbk and its competitors.
Is PT Kalbe Farma Tbk's Accumulated Depreciation too high?
PT Kalbe Farma Tbk's current Accumulated Depreciation is € Mil. Overall, PT Kalbe Farma Tbk has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Accumulated Depreciation compare to LLY and JNJ?
PT Kalbe Farma Tbk's Accumulated Depreciation of € Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Drug Manufacturers company?
A good Accumulated Depreciation depends on the Drug Manufacturers industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on PT Kalbe Farma Tbk and its competitors. PT Kalbe Farma Tbk's current Accumulated Depreciation is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
PT Kalbe Farma Tbk (FRA:LCLA) has a current Accumulated Depreciation of € Mil. The stock's GF Value™ is €0.07, compared to a current price of €0.04 — trading 42.9% below its estimated fair value. The current Accumulated Depreciation is € Mil. PT Kalbe Farma Tbk's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current Accumulated Depreciation is € Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?

Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued. The current stock price of €0.04 is trading 42.9% below its estimated GF Value™ of €0.07.

Key valuation signals for FRA:LCLA:

  • Accumulated Depreciation: € Mil
  • GF Value™: €0.07 vs. price of €0.04 (42.9% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Kalbe Farma Tbk Business Description

Address Jalan Let. Jend. Suprapto Kav. 4, Gedung KALBE, Cempaka Putih, P.O. Box 3105, Jakarta, IDN, 10510
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
81GF Score

Get the complete analysis for FRA:LCLA

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.04
Price
€0.07
GF Value